Psilocybin Without Hallucinations? What Two New Studies Found

Why Some People Stay Away from Psilocybin

You may have heard a lot about the healing power of magic mushrooms. Studies show psilocybin can help with depression, anxiety, addiction, and OCD. The results are often dramatic — and long-lasting.

But here is the part that stops many people: psilocybin causes hallucinations. You may see things that are not there, lose your sense of time, or feel like you are no longer yourself. For some people, that sounds interesting. For others, it sounds terrifying.

People with a history of psychosis, schizophrenia, or certain mental illnesses cannot safely take psilocybin at all. The hallucinations carry real risks for them. And even for healthy people, a full psychedelic experience requires careful preparation, a safe space, and often a trained guide — which makes treatment expensive and hard to access.

So scientists have been asking a simple but powerful question: Do you actually need to hallucinate to get better?

What Happens in Your Brain When You Take Psilocybin

To understand the new research, it helps to know a little about how psilocybin works. When you eat magic mushrooms, your body converts psilocybin into a substance called psilocin. Psilocin then travels to the brain and binds to serotonin receptors — the same receptors that regulate mood, sleep, and appetite.

Until now, scientists mainly focused on one of those receptors: the serotonin 2A receptor. This receptor is responsible for the hallucinations. If you activate it strongly, you trip. That is why researchers assumed the hallucinations and the healing effects were part of the same process — you could not have one without the other.

New research suggests that assumption was wrong. You can read more about the basics in our article on how psilocybin and psilocin work.

Study 1: Dartmouth Finds a New Receptor (January 2026)

Researchers at Dartmouth College in the United States were studying how psilocybin reduces depression and anxiety in mice. They discovered something unexpected: the beneficial effects were not only coming from the 2A receptor. They were also coming from a completely different receptor — the serotonin 1B receptor.

The 1B receptor does not cause hallucinations. In fact, it is already a target for common anti-migraine medications. Activating it does not produce any psychedelic effects at all.

"When people think about psilocybin, they think about hallucinations," said Katherine Nautiyal, the senior researcher behind the study. "We thought the beneficial effects might be found in other receptors — and we were right."

This finding was published in the journal Molecular Psychiatry. It opens the door to developing new psilocybin-based medicines that work through the 1B receptor — without triggering hallucinations at all.

Study 2: Italian Chemists Create Psilocin Without the Trip (March 2026)

Around the same time, a team of chemists at the University of Padua in Italy took a different approach. Instead of studying receptors, they redesigned the molecule itself.

They created five new chemical versions of psilocin — the active substance in magic mushrooms. Each version was engineered to release psilocin into the brain more slowly and steadily. The idea: if psilocin reaches the brain gradually instead of all at once, maybe the brain does not react as intensely. Less spike, less hallucination — but still enough serotonin activity to produce therapeutic benefits.

They tested the most promising version — called "4e" — in mice. Here is what they found:

In short: the molecule worked like psilocybin on the serotonin system, but acted much less like a psychedelic. The research was published in the Journal of Medicinal Chemistry by the American Chemical Society.

"Our findings are consistent with a growing scientific perspective suggesting that psychedelic effects and serotonergic activity may be dissociated," said lead researcher Andrea Mattarei. "This opens the possibility of designing new therapeutics that retain beneficial biological activity while reducing hallucinogenic responses."

Why This Is Important for People Who Would Never Take Mushrooms

Right now, psilocybin therapy is not accessible to everyone. You need a clinical setting, a trained guide, hours of preparation, and the willingness to fully surrender to a psychedelic experience. That works for some people. But many others simply will not — or cannot — do that.

Think about:

These two studies point to a future where psilocybin-inspired medicines could be taken like a regular antidepressant — no trip required, no guide needed, no loss of control. A daily capsule, or a targeted injection, that works through the same brain pathways — just without the fireworks.

It is still early. Both studies were done in mice, not humans. Clinical trials in people are the next step, and that will take years. But the direction is clear.

Does This Mean Hallucinations Are Useless?

Not necessarily. Many researchers believe the psychedelic experience itself — the sense of dissolution, the emotional breakthrough, the shift in perspective — is also part of why psilocybin therapy works so well. Some patients describe their trip as one of the most meaningful experiences of their lives, and that meaning seems to support lasting change.

So the debate in science is now nuanced: For some conditions and some people, the full experience may matter. For others, it may not.

The goal is not to replace the psychedelic experience. The goal is to make psilocybin's benefits available to more people — including those for whom a full trip is not suitable, safe, or desired. You can learn more about how psilocybin works in the mind and how psychedelics are transforming mental health treatment.

What About Microdosing?

If you are already curious about psilocybin without the full trip, you may have heard of microdosing. Microdosing means taking a very small amount of psilocybin — far below what causes any hallucinations — on a regular schedule. Many people report improved mood, focus, and emotional balance without any perceptual effects.

The new research on non-hallucinogenic receptors actually supports what microdosers have been reporting for years: that sub-psychedelic doses can still influence serotonin pathways in meaningful ways. The 1B receptor, in particular, may be exactly what low doses are activating.

If you want to explore microdosing yourself, here are two good places to start:

You can also explore our full microdosing category or read our in-depth microdosing guide to learn more.

The Bigger Picture

These two studies are part of a much larger shift in science. For decades, psilocybin was illegal almost everywhere and hardly studied. Now it has FDA Breakthrough Therapy designation for depression, and hundreds of clinical trials are running worldwide.

The question used to be: Does psilocybin work? The answer to that is increasingly clear: yes, remarkably well. The question now is: How exactly does it work — and can we make it work better for more people?

That is exactly what these studies are exploring. And the answers they are finding could change who has access to psilocybin-based healing — not just curious psychonauts, but millions of people who have been waiting for a treatment that actually works.